An update on renal replacement therapy in Europe: ERA-EDTA Registry data from 1997 to 2006

Nephrology Dialysis Transplantation

Volumn 24, Issue 12, 2009, Pages 3557-3566

  Kramer, Anneke ^a   Stel, Vianda ^a   Zoccali, Carmine ^b   Heaf, James ^c   Ansell, David ^d   Grönhagen Riska, Carola ^e   Leivestad, Torbjørn ^f   Simpson, Keith ^g   Pálsson, Runólfur ^h   Postorino, Maurizio ^b   Jager, Kitty ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^d SOUTHMEAD HOSPITAL   (United Kingdom)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^f OSLO UNIVERSITY HOSPITAL   (Norway)

^g Scottish Renal Registry   (United Kingdom)

^h LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

Author keywords

Europe; Incidence; Renal replacement therapy; Survival

Indexed keywords

AGED; ARTICLE; CONTROLLED STUDY; EUROPE; FEMALE; GROUPS BY AGE; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PERITONEAL DIALYSIS; PREVALENCE; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; RENOVASCULAR DISEASE; RISK FACTOR; SEX DIFFERENCE; SURVIVAL RATE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; EUROPE; FEMALE; HUMANS; INFANT; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; REGISTRIES; RENAL REPLACEMENT THERAPY; TIME FACTORS; YOUNG ADULT;

EID: 71049148482     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp519     Document Type: Article

References (46)

1. Brunner FP, Selwood NH. Results of renal replacement therapy in Europe, 1980 to 1987. Registration Committee of the EDTA-ERA. Am J Kidney Dis 1990; 15: 384-396
2. Eggers PW, Connerton R, McMullan M. The Medicare experience with end-stage renal disease: trends in incidence, prevalence, and survival. Health Care Financ Rev 1984; 5: 69-88
3. Elinder CG, Jones E, Briggs JD et al. Improved survival in renal replacement therapy in Europe between 1975 and 1992. An ERA-EDTA Registry study. Nephrol Dial Transplant 1999; 14: 2351-2356 (Pubitemid 29462471)
4. Meier-Kriesche HU, Ojo AO, Port FK et al. Survival improvement among patients with end-stage renal disease: trends over time for transplant recipients and wait-listed patients. J Am Soc Nephrol 2001; 12: 1293-1296
5. Stengel B, Billon S, van Dijk PC et al. Trends in the incidence of renal replacement therapy for end-stage renal disease in Europe, 1990-1999. Nephrol Dial Transplant 2003; 18: 1824-1833
6. van Dijk PC, Jager KJ, de CF et al. Renal replacement therapy in Europe: the results of a collaborative effort bythe ERA-EDTA registry and six national or regional registries. Nephrol Dial Transplant 2001; 16: 1120-1129
7. Jager KJ, van Dijk PC. Has the rise in the incidence of renal replacement therapy in developed countries come to an end? Nephrol Dial Transplant 2007; 22: 678-680
8. Gansevoort RT, Van Der HB, Stegeman CA et al. Trends in the incidence of treated end-stage renal failure in The Netherlands: hope for the future? Kidney Int Suppl 2004; 66: S7-10
9. Sorensen VR, Hansen PM, Heaf J et al. Stabilized incidence of diabetic patients referred for renal replacement therapy in Denmark. Kidney Int 2006; 70: 187-191
10. ERA-EDTA Registry. ERA-EDTA Registry 2006 Annual Report. Academic Medical Center, Department of Medical Informatics, Amsterdam, The Netherlands, June, 2008
11. National Cancer Institute, Statistical Research and Applications Branch. Joinpoint Regression Program, Version 3.3, April 2008. Available at http://srab.cancer.gov/joinpoint
12. Kim HJ, Fay MP, Feuer EJ et al. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 2000; 19: 335-351
13. US Renal Data System. USRDS 2008 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2008
14. Foley RN, Collins AJ. End-stage renal disease in the United States: an update from the United States Renal Data System. J Am Soc Nephrol 2007; 18: 2644-2648
15. McDonald S, Chang S, Excell L. New patients commencing treatment in 2006 [Chapter 2], ANZDATA Registry Report 2007. Australia and New Zealand Dialysis and Transplant Registry, Adelaide, South Australia
16. McDonald S, Russ G. New patients commencing treatment in 2002 [Chapter 2], ANZDATA Registry Report 2003. Australia and New Zealand Dialysis and Transplant Registry, Adelaide, South Australia
17. Canadian Institute for Health Information. 2007 Annual Report-Treatment of End-Stage Organ Failure in Canada, 1996-2005, CIHI, Ottowa, 2008
18. The ESRD Incidence Study Group. Geographic, ethnic, age-related and temporal variation in the incidence of end-stage renal disease in Europe, Canada and the Asia-Pacific region, 1998-2002. Nephrol Dial Transplant 2006; 21: 2178-2183
19. Jager KJ, van Dijk PC, Dekker FW et al. The epidemic of aging in renal replacement therapy: an update on elderly patients and their outcomes. Clin Nephrol 2003; 60: 352-360
20. Wild S, Roglic G, Green A et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053
21. Kearney PM, Whelton M, Reynolds K et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365: 217-223
22. El NM. The global challenge of chronic kidney disease. Kidney Int 2005; 68: 2918-2929
23. White SL, Cass A, Atkins RC et al. Chronic kidney disease in the general population. Adv Chronic Kidney Dis 2005; 12: 5-13
24. National Kidney Foundation-K/DOQI. Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification: update 2002. Am J Kidney Dis 2002; 39: S1-S266
25. Bello AK, Nwankwo E, El Nahas AM. Prevention of chronic kidney disease: a global challenge. Kidney Int Suppl 2005; S11-S17 (Pubitemid 43307842)
26. Devins GM, Mendelssohn DC, Barre PE et al. Predialysis psychoed-ucational intervention and coping styles influence time to dialysis in chronic kidney disease. Am J Kidney Dis 2003; 42: 693-703
27. Keith DS, Nichols GA, Gullion CM et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004; 164: 659-663
28. Levin A, Djurdjev O, Beaulieu M et al. Variability and risk factors for kidney disease progression and death following attainment of stage 4 CKD in a referred cohort. Am J Kidney Dis 2008; 52: 661-671
29. Johnson ES, Thorp ML, Yang X et al. Predicting renal replacement therapy and mortality in CKD. Am J Kidney Dis 2007; 50: 559-565
30. National Kidney Foundation-K/DOQI. Clinical practice guidelines for hemodialysis and peritoneal dialysis adequacy. Am J Kidney Dis 1997; 30: S1-S136
31. ERA-EDTA. European Best Practice Guidelines. Section I. Measurement of renal function, when to refer and when to start dialysis. Nephrol Dial Transplant 2002; 17(Suppl 7): 7-15
32. Rosansky SJ, Clark WF, Eggers P et al. Initiation of dialysis at higher GFRs: is the apparent rising tide of early dialysis harmful or helpful? Kidney Int 2009; 76: 257-261
33. Adachi Y, Nakagawa Y, Nishio A. Icodextrin preserves residual renal function in patients treated with automated peritoneal dialysis. Pe r i t Dial Int 2006; 26: 405-407
34. Davies SJ. Mitigating peritoneal membrane characteristics in modern peritoneal dialysis therapy. Kidney Int Suppl 2006; 70: S76-S83
35. Jager KJ, Merkus MP, Dekker FW et al. NECOSAD Study Group. Mortality and technique failure in patients starting chronic peritoneal dialysis: results of The Netherlands Cooperative Study on the Adequacy of Dialysis. Kidney Int 1999; 55: 1476-1485
36. Konings CJ, Kooman JP, Schonck M et al. Effect of icodextrin on volume status, blood pressure and echocardiographic parameters: a randomized study. Kidney Int 2003; 63: 1556-1563
37. Krediet RT. 30 years of peritoneal dialysis development: the past and the future. Perit Dial Int 2007; 27(Suppl 2): S35-S41
38. Lee HY, Park HC, Seo BJ et al. Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (Balance). Perit Di al Int 2005; 25: 248-255
39. Marron B, Remon C, Perez-Fontan M et al. Benefits of preserving residual renal function in peritoneal dialysis. Kidney Int Suppl 2008; 73: S42-S51
40. Pecoits-Filho R, Stenvinkel P, Heimburger O et al. Beyond the membrane-the role of new PD solutions in enhancing global bio-compatibility. Kidney Int Suppl 2003; 64: S124-S132
41. Williams JD, Topley N, Craig KJ et al. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 2004; 66: 408-418
42. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351: 2715-2729
43. Kuypers DR, Vanrenterghem YC. Tailoring immunosuppressive therapy. Nephrol Dial Transplant 2002; 17: 2051-2054
44. Tazza L, Di NA, Bossola M et al. Ageing of patients on chronic dialysis: effects on mortality-A 12-year study. Nephrol Dial Transplant 2008; 24: 940-947
45. Devins GM, Mendelssohn DC, Barre PE et al. Predialysis psychoed-ucational intervention extends survival in CKD: a 20-year follow-up. Am J Kidney Dis 2005; 46: 1088-1098
46. Goldstein M, Yassa T, Dacouris N et al. Multidisciplinary predialysis care and morbidity and mortality of patients on dialysis. Am J Kidney Dis 2004; 44: 706-714